Drug
Glepaglutide clinical trials
Also written ZP1848.
- studies test it
- 11
- open now
- 1
- in phase 3
- 6
- first study started
- 2009
Keep track of what changes. Save the glepaglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- ZP1848
- 11
Studies by the year they started
11 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 1
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses glepaglutide is read from its arms, and is right about nine times in ten.
Testing it · 11
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSRecruitingPhase 3Zealand PharmaNCT07197944Written as Glepaglutide
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialCompletedPhase 3Zealand PharmaNCT04881825Written as Glepaglutide
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSCompletedPhase 3Zealand PharmaNCT03905707Written as glepaglutide
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeActive, not recruitingPhase 3Zealand PharmaNCT07228403Written as Glepaglutide 10 mg
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)CompletedPhase 3Zealand PharmaNCT03690206Written as glepaglutide
- The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel SyndromeCompletedPhase 3Zealand PharmaNCT04991311Written as Glepaglutide
- A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.CompletedPhase 1Zealand PharmaNCT04318743Written as Glepaglutide
- Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal FunctionCompletedPhase 1Zealand PharmaNCT04178447Written as Glepaglutide
- Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy SubjectsCompletedPhase 1Zealand PharmaNCT03279302Written as Glepaglutide
- A Phase 2 Trial Testing ZP1848 in Patients With SBSCompletedPhase 2Zealand PharmaNCT02690025Written as ZP1848
- Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending DoseCompletedPhase 1Zealand PharmaNCT00868660Written as ZP1848
Codes
What other systems call glepaglutide · ClinicalTrials.gg INT002118
- MeSH (NLM) C000731534glepaglutideOne source NLM
- UNII (FDA) 4M3C1913N6GLEPAGLUTIDEConfirmed FDA, NLM
- NCI Thesaurus C166765GlepaglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731534 | glepaglutide | One source NLM |
| UNII (FDA) | 4M3C1913N6 | GLEPAGLUTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C166765 | Glepaglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.